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Abstract
Background: Pulmonary vascular structure remodeling (PVSR) is a hallmark of pulmonary hypertension. P27
kip1,
one of critical cyclin-dependent kinase inhibitors, has been shown to mediate anti-proliferation effects on various
vascular cells. Beta-estradiol (b-E2) has numerous biological protective effects including attenuation of hypoxic
pulmonary hypertension (HPH). In the present study, we employed b-E2 to investigate the roles of p27
kip1 and its
closely-related kinase (Skp-2) in the progression of PVSR and HPH.
Methods: Sprague-Dawley rats treated with or without b-E2 were challenged by intermittent chronic hypoxia
exposure for 4 weeks to establish hypoxic pulmonary hypertension models, which resemble moderate severity of
hypoxia-induced PH in humans. Subsequently, hemodynamic and pulmonary pathomorphology data were
gathered. Additionally, pulmonary artery smooth muscle cells (PASMCs) were cultured to determine the anti-
proliferation effect of b-E2 under hypoxia exposure. Western blotting or reverse transcriptional polymerase chain
reaction (RT-PCR) were adopted to test p27
kip1, Skp-2 and Akt-P changes in rat lung tissue and cultured PASMCs.
Results: Chronic hypoxia significantly increased right ventricular systolic pressures (RVSP), weight of right ventricle/
left ventricle plus septum (RV/LV+S) ratio, medial width of pulmonary arterioles, accompanied with decreased
expression of p27
kip1 in rats. Whereas, b-E2 treatment repressed the elevation of RVSP, RV/LV+S, attenuated the PVSR
of pulmonary arterioles induced by chronic hypoxia, and stabilized the expression of p27
kip1. Study also showed that
b-E2 application suppressed the proliferation of PASMCs and elevated the expression of p27
kip1 under hypoxia
exposure. In addition, experiments both in vivo and in vitro consistently indicated an escalation of Skp-2 and
phosphorylated Akt under hypoxia condition. Besides, all these changes were alleviated in the presence of b-E2.
Conclusions: Our results suggest that b-E2 can effectively attenuate PVSR and HPH. The underlying mechanism
may partially be through the increased p27
kip1 by inhibiting Skp-2 through Akt signal pathway. Therefore, targeting
up-regulation of p27
kip1 or down-regulation of Skp-2 might provide new strategies for treatment of HPH.
Background
Pulmonary hypertension is a common complication of
chronic hypoxic lung diseases, characterized by sus-
tained elevation of pulmonary artery pressure and
vascular resistance [1]. Pulmonary vascular structure
remodeling (PVSR) is a hallmark of severe and advanced
pulmonary hypertension, presenting several histological
changes such as intima thickening, media hyperplasia
and adventitia widening, peripheral vessels musculariza-
tion and vasoocclusive plexiform lesions [1,2]. Those
changes finally lead to severe pulmonary hypertension,
right ventricular hypertrophy and right heart failure,
resulting in high morbidity and mortality [3]. Generally,
there are 5 subsets of pulmonary hypertension classified
according to the latest guidelines for the diagnosis and
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5 subsets, pulmonary arterial hypertension (PAH),
whose inducements including idiopathic, heritable, and
connective tissue diseases, is predominantly suffered by
women. According to epidemiological studies, there are
about 2-3 times as many female as male patients [5-7].
The pathological lesions of PAH mainly affect the small
pulmonary arteries (<500 μm of diameter), and are fea-
tured by medial hypertrophy, intimal proliferation and
fibrotic changes, adventitial thickening, complex lesions,
and thrombotic lesions [3,8]. Compared with PAH, the
pathological changes of pulmonary hypertension due to
lung diseases and/or hypoxia are characterized by med-
ial hypertrophy and intimal obstructive proliferation of
the distal pulmonary arteries [4,9]. In general, the sever-
ity of pulmonary hypertension due to lung diseases and/
or hypoxia is usually from mild to moderate compared
with PAH [4,10].
Despite the fact that PAH associated with idiopathic,
heritable, and connective tissue diseases largely occurred
to women, researchers reported that women with
chronic obstructive pulmonary diseases exhibited a
lower risk of mortality than men [11]. Consistent with
this observation, earlier studies on HPH animal models
have demonstrated that female rats developed less
severe PH than male [12,13].
Current therapeutic strategies to pulmonary hyperten-
sion mainly include anticoagulation, prostacyclin, lung
transplantation, atrial septostomy, and pulmonary endar-
terectomy [4,8]. New therapeutic strategies, such as
prostacyclin analogues, endothelin-1 receptor antago-
nists, phosphodiesterase inhibitors and L-arginine, are
emerging [14]. Furthermore, genetic therapy, stem cell
therapy, and anti-proliferative therapies are also being
under explored in laboratories [15].
Studies about estrogen have shown its various cardio-
vascular protective effects including prevention of coron-
ary artery atherosclerosis [16], vasodilation of vessels
[17], reduction of heart attacks [18] and attenuation of
heart remodeling [19], etc. The molecular mechanisms of
estrogen’s cardiovascular protective effects involve
decreasing induction of erythropoietin [20], inhibiting
endothelin-1 expression [21], initiating nitride oxide
synthesis [22], activating prostacyclin synthesis [23], and
downregulating various adhension molecules [24]. Inves-
tigations also showed that estrogen can effectively relieve
pulmonary hypertension of various etiologies including
drugs, sclerosis, idiopathic, and other systematic diseases
[25,26]. Additionally, Earley and Mukundan et al found
estrogen markedly alleviated chronic hypoxia-induced
pulmonary hypertension through modulating different
molecules’ expression [20,27]. Moreover, studies also
revealed the anti-proliferation effects of estrogen in other
proliferative vascular diseases [28,29].
Pulmonary vascular proliferation and remodeling are
considered to be the central pathogenesis in the process
of chronic hypoxia-induced pulmonary hypertension
(HPH) [30]. In normal situation, most of the PASMCs
in healthy adult are in a quiescent state [31], while pro-
liferative PASMCs are found in the pulmonary hyper-
tension arterioles which contribute to media thickening
and vascular resistance [30,32]. Recent experimental stu-
dies indicate that cell cycle inhibition holds great poten-
tial as a therapeutic strategy for vascular proliferative
diseases [33,34]. The cell cycle progression is regulated
by kinds of cyclin-dependent kinases (CDKs) and their
specific regulatory cyclins. The cyclin-dependent kinases
inhibitors include INK4 family and cip family which can
inhibit the activity of the CDK-cyclin complexes. The
Cip/Kip family can inhibit all cyclin/CDK complexes
in vitro,i nw h i c hp 2 7
kip1 is one of the core members
controlling the cell cycle progression [35,36].
Though p27
kip1 was found years ago [37], it was
recently recognized as an anti-oncogene protein [38,39].
Subsequent studies revealed p27
kip1 as an inhibitor of
vascular smooth muscle cell, which might participate in
vascular proliferative diseases [40]. Fouty and colleagues
forward demonstrated that p27
kip1 is important in mod-
ulating PASMCs [41]. Moreover, Yu et al found that
decreased functional p27
kip1 may contribute to PVSR
associated with pulmonary hypertension, and up-regu-
lated p27
kip1 mediate the inhibition effect on HPH [42].
The S phase kinase associated protein 2 (Skp-2) was
found as a member of the large eukaryotic family of
F-box proteins which functions specifically for the
degradation of p27
kip1 [43]. Studies in these years
demonstrated Skp-2 as a proto-oncogene and a positive
regulator of cell cycle which involved in many diseases
[44,45]. After activated by the phosphorylated Akt (Akt-
P), Skp-2 mediates the proteolysis of p27
kip1 [46]. Now
cancer therapeutic strategies targeting Skp-2 are becom-
ing a hot topic [47,48].
In view of the mentioned above, we hypothesized that
b-E2 may act on the Akt signal pathway and keep
p27
kip1 from being degraded through down-regulation
of Skp-2 under hypoxia condition. In this way, b-E2
may ameliorate chronic hypoxia-induced PVSR and pul-
monary hypertension. Therefore, we adopted b-E2 to
explore the roles of p27
kip1 and Skp-2 in the evolution
of PVSR and HPH in vivo. Further, we verified their
effects on cultured PASMCs in vitro.
Methods
Experimental groups
All animal experiments were approved by the Animal
Care and Use Committee of the Fourth Military Medical
University and complied with the Declaration of the
National Institutes of Health Guide for Care and Use of
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Male Sprague-Dawley rats (body weight 180-230 g) from
the animal center of the Fourth Military Medical
University (Xi’an, China) were used for all the experiments
in our study.
Animals were randomly divided into 4 groups: 1)
normoxia group, n = 7, 2) normoxia group treated with
b-E2 (100 μg/kg via intraperitoneal injection), n = 7, 3)
chronic hypoxia group, n = 7, and 4) chronic hypoxia
group treated with b-E2 (100 μg/kg via intraperitoneal
injection), n = 7. Animals designated for exposure to
chronic hypoxia were housed intermittently in a hypoba-
ric hypoxia chamber depressurized to 380 mmHg (oxy-
gen concentration reduced to about 10%) and under
hypoxia exposure for 10 h/d continuing 4 weeks. The
normoxic control rats were housed at ambient baro-
metric pressure (~718 mmHg, 21% oxygen). All animals
were maintained in a 12:12-h light-dark cycle condition.
The room temperature was air-conditioned at 25°C.
Hemodynamic experiments and tissue preparation
After 4 weeks hypoxia exposure, the animals were
anesthetized with 20% ethylurethanm (4 ml/kg i.p.), and
a soft silicagel catheter linked to a Powerlab system (AD
Instruments, Colorado Springs, CO, AUSTRALIA) was
inserted into the right jugular vein. There were special
pressure waveforms displayed on the monitor when the
catheter arrived in the right ventricle chamber. The
right ventricle peak systolic pressure (RVSP) was then
recorded. Meanwhile, the mean carotid artery pressure
(mCAP) was recorded via a special catheter inserted
into the carotid artery.
After the hemodynamic data were recorded, sternot-
omy surgery was performed. Lungs together with heart
were harvested and put in a culture plate with cold PBS.
The weight of right ventricle (RV) and left ventricle plus
septum (LV+S) were obtained, and the ratio of (RV/LV
+S) was calculated as an index of RV hypertrophy. The
lungs were dissected into 3-mm-thick slices at the same
point (the lower lobe of the right lung) and placed in
neutral buffer (pH 7.4) containing 10% formalin. The
remained lungs were frozen in -80°C freezer for subse-
quent experiments.
Morphological investigation
After soaked in 10% formalin for 72 hours, the slices
were embedded in paraffin and sectioned into 4-μm-
thick sections and hematoxylin and eosin staining was
done. The stained lung sections were processed by a
pathologist for light microscopic observation and photo
images analysis. Pulmonary arteries, external diameter of
which ranged from 50 to 200 μm, 5-6 vessels with
approximate round shape were obtained from each indi-
vidual animal, total 40 arteries were got from every
group. The average size of the obtained vessels was
78 μm. The outside diameter and inside diameter of
pulmonary arterioles were measured by an image-
processing program (Image-Pro Plus, Version 5.1, Media
Cybernetics, USA). The medial wall thickness, the cross
sectional area of medial wall, and the total cross sec-
tional vessel area were obtained. Pulmonary vascular
structure remodeling was assessed by percent medial
wall thickness (MT%) and percent medial wall area
(MA%) two indices: (MT%) = 100 × (medial wall thick-
ness)/(vessel semi-diameter); (MA%) = 100 × (cross-
sectional medial wall area)/(total cross-sectional vessel
area). All the morphological analysis was conducted in
a double-blind method.
Cell culture and treatment
Pulmonary artery smooth muscle cells (PASMCs) were
obtained by tissue explant culturing method. Pulmonary
arteries were isolated from adult male Sprague-Dawley
rats as described above. After the adventitial layers
together with surrounding tissue were removed, the pul-
monary arteries were dissected into small pieces and
placed in a culture flask. The flask was overturned
placed and Dulbecco Eagle’s minimum essential medium
(DMEM) (HyClone, Logan, UT, USA) was added in.
After 2-4 hours, the flask was carefully turned over, and
the medium immersed the tissue pieces. The explanted
tissue was cultured in DMEM supplemented with 100
U/ml penicillin, 0.1 mg/ml streptomycin, 2 mM L-gluta-
mine, and 10% FBS and grown in humidified incubators
(HH·CP-01W, Shanghai Boxun Industry & Commerce
Co., Ltd. Medical Equipment Factory, Shanghai, China)
at 37°C in 95% O2 ,5 %C O 2. The PASMCs grew out in
about a week, and cell passage was performed when the
cells grew to 70% confluence. Cells were used between
passages 3 and 6. Smooth muscle cell identity was veri-
fied by positive staining for smooth muscle a-actin
(mouse monoclonal antibody; Sigma, USA) at each pas-
sage (>95% of cells stained positive for smooth muscle
a-actin). The cells were seeded at 1 × 10
7 cells per well
in cell culture Petri dishes (JET BIOFIL inc, Canada)
and allowed to grow for 2 days. Then the cells were
undergone serum-starvation for 36 hours. The media
was then changed to containing 5% FBS phenol-red-free
DMEM (HyClone, Logan, UT, USA) with b-E2 in var-
ious dosages (10
-5,1 0
-7,1 0
-9 mol/L). There were total 5
groups for cell study, one normoxia group, and three
hypoxia exposure groups treated with three different
dosages of b-E2, and one under hypoxia exposure group
alone. Cells were cultured either in 21% oxygen or 2%
oxygen condition (HERAcell 240, Heraeus Inc, Ger-
many) for another 48 hours. After treatment the cell
lysates were obtained as described below for the Wes-
tern blotting and RT-PCR analysis.
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To investigate the inhibition of b-E2 on hypoxia-
induced proliferation of PASMCs, 3-(4,5-dimethylthia-
zal-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) tests
were completed. In a word, cells were seeded in 96-well
cell culture Petri dishes at 4 × 10
4 cells per well accord-
ing to the groups designated above and 3 dosages of
b-E2 (10
-5,1 0
-7,1 0
-9 mol/L) was added in. After cul-
tured for 48 hours under normoxia condition or hypoxia
exposure, solution MTT was added into each well in a 5
mg/mL concentration. Cells were cultured for another 4
hours, and then dimethyl sulfoxide (DMSO) was added
in. After vibrating for 10 minutes, the optical density
values were detected at 490 nm wavelength by using a
spectrophotometer (PowerWave XS, BioTek Inc,
Vermont, USA).
Western blotting analysis
Total lysates were obtained from harvested lung tissue
a n dc u l t u r e dP A S M C s .L u n gh o m o g e n a t e sw e r ep r e -
pared in RIPA lysis buffer, containing 50 mM Tris (pH
7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deox-
ycholate, 0.1% SDS, 2 mM NaF, 5 mM EDTA (pH 8.0),
1 mM sodium orthovanadate (Beyotime Inc, Jiangsu,
China). The protease inhibitor of phenylmethylsulfonyl
fluoride (PMSF, 1 mM) was added to the RIPA buffer in
advance. Equivalent amounts of protein (30 μg) from
each sample were separated on 12% SDS-polyacrylamide
gels, and then transferred onto 0.22 μM nitrocellulose
filter membranes (Millipore, Bedford, USA). The pri-
mary antibodies were p27
kip1 antibody (1:1000; Milli-
pore, Bedford, USA), Skp-2 polyclonal antibody (1:50;
Abcam, Cambridge, UK) and Akt-P (1:500; Cell Signal-
ing Technology, Inc., Massachusetts, USA). The signals
were detected by ECL kit (BestBio Inc, Shanghai, China).
RNA extraction and reverse-transcription polymerase
chain reaction (RT-PCR) investigation
Total RNA of lung tissue and cultured PASMCs were
extracted by using Trizol agent (Invitrogen, Carlsbad,
CA, USA). M-MLV reverse transcripase kits (BestBio
Inc, Shanghai, China) were used to synthesize first-
strand cDNA from 2.5 μg per sample of total RNA
according to the manufacturer’si n s t r u c t i o n s .T h ep r i -
mer pairs were designed by primer premier 5 (PREMIER
Biosoft International, Palo Alto CA, USA), and original
information of cDNA were aligned in the GeneBank.
The primers were checked and synthesized by Gene-
script Company (Nangjing, China). The primer pairs for
p27
kip1 PCR (319 bp) were (forward chain) 5’-CTTGGA-
GAAGCACTGCCGAGAT-3’ and (reverse chain)
5’-CCCTGGACACTGCTCCGCTA-3’,f o rS k p - 2( 3 9 6
bp) were (forward) 5’-TAAGCGTTAGGTCTTTGGAA-
3’ and (reverse) 5’-TGGTTGTGTGTGTCTGTGTC3’,
and for the housekeeping gene b-actin (270 bp) were
(forward) 5’-ATCATGTTTGAGACCTTCAACA-3’ and
(reverse) 5’-CATCTCTTGCTCGAAGTCCA-3’ respec-
tively. PCR program for p27
kip1 was started by a 5 min
denaturation procedure at 95°C, followed by 35 cycles of
95°C for 30 s, 51°C for 30 s and 72°C for 1 min, and a
final extension at 72°C for 10 min; for Skp-2 was initiated
by a 5 min denaturation step at 95°C, followed by 35
cycles of 95°C for 30 s, 59°C for 30 s and 72°C for 1 min,
and a final extension at 72°C for 10 min; and for b-actin
was began with a 5 min denaturation step at 95°C, fol-
lowed by 35 cycles of 95°C for 30 s, 55°C for 30 s and 72°
C for 1 min, and a final extension at 72°C for 10 min.
After amplification was done, the products were sepa-
rated by 1% agarose gel (containing 0.5 μg/ml ethidium
bromide) electrophoresis. The gels were visualized by a
gel visualizing system (BioSens SC 810, Shanghai Bio-
Tech Inc, Shanghai, China) and densitometry was calcu-
lated using the imaging software (BioSens Digital Ima-
ging 5, Shanghai Bio-Tech Inc, Shanghai, China).
Statistical analyses
All values were expressed as mean ± SD. Statistical ana-
lysis was processed by using one-way ANOVA, followed
by LSD test for post hoc multiple comparisons (SPSS
for Windows version 16.0, Chicago, USA). Significant
difference was accepted at P < 0.05.
Results
Beta-estradiol treatment attenuated chronic
hypoxia-induced pulmonary artery remodeling
and pulmonary hypertension in rats
The right ventricular systolic pressure (RVSP) was mea-
sured by catheterization via jugular vein to right ventri-
cle, which substitutes for the pulmonary artery pressure.
After 4 weeks hypoxia exposure, the RVSP of hypoxia
group was significantly elevated compared with the nor-
moxia group (47.36 ± 3.47 vs. 24.90 ± 1.66 mmHg;
Table 1, n = 7, P <0 . 0 1 ) .I nt h eh y p o x i a + b-E2 group,
RVSP was significantly lower than the chronic hypoxia
exposed group (35.17 ± 1.67 vs. 47.36 ± 3.47 mmHg;
Table 1, n = 7, P < 0.01), even it was a little higher than
those of normoxia group. There was no significant dif-
ference of the RVSP between the normoxia group and
the normoxia treated with b-E2 group (24.90 ± 1.66 vs.
25.17 ± 1.20 mmHg; Table 1, n = 7, P <0 . 0 1 ) .T h e r e
was no significant difference in the mCAP between each
group (as shown in Table 1).
Wall-thickened pulmonary arterioles with medial
smooth muscle cell proliferation and hypertrophy, and
inflammatory cell infiltration were observed in the
chronically hypoxia-exposed rats lungs compared with
those in the normoxia group. The adventitial thickening
together with extracellular matrix accumulation, intima
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observed in those rats’ lungs under chronic hypoxia
exposure. Destruction of lung alveolar structure can also
be seen in the chronic hypoxia treated rats lungs. The
vessel changes as described above in the hypoxia+b-E2
group were better than those of the hypoxia group
(Figure 1a, Hematoxylin and eosin staining).
Furthermore, the medial wall thickness (MT)% of the
arterioles, the index of pulmonary artery remodeling,
was significantly elevated after chronic hypoxia exposure
versus the normoxia group (Figure 1b, n = 40, P < 0.01).
In the hypoxia+b-E2 group, (MT)% was notably smaller
than in the hypoxia group (Figure 1b, n = 40, P < 0.01).
There was no significant difference of the (MT)%
between the normoxia group and normoxia+b-E2 group
(Figure 1b). In accordance with the medial wall thick-
ness, the medial wall area (MA)% in the hypoxia group
was also significantly higher than in the normoxia group
(Figure 1c, n = 40, P < 0.01). Consistent with the result
of (MT)%, there was no significant difference of the
(MA)% between the normoxia group and normoxia
+b-E2 group (Figure 1c). Beta-estradiol treatment signif-
icantly decreased the (MA)% of the arterioles after
hypoxia exposure compared with the hypoxia group
(Figure 1c, n = 40, P < 0.01). Nevertheless, both (MT)%
and (MA)% were still higher than that of the normoxia
group (Figure 1b, c).
Cell proliferation analysis of PASMCs
The OD values were representatives of the cells number.
As shown in Figure 2, hypoxia exposure dramatically
increased the OD values compared with those of the
normoxia group (Figure 2, P < 0.01), that is, hypoxia
exposure significantly increased the cell proliferation.
The hypoxia-induced proliferation of PASMCs were
obviously inhibited by three various dosages of b-E2
treatment (Figure 2, P < 0.01).
Protein expression of p27
kip1 and Skp-2 in rat lung
tissue and cultured PASMCs
Aiming to know whether p27
kip1 and Skp-2 were
involved in chronic hypoxia-induced pulmonary hyper-
tension and artery remodeling, the protein levels of
p27
kip1 and Skp-2 in the 4 experimental groups were
compared. Western blotting results showed that the rela-
tive p27
kip1 level in hypoxia group was significant lower
than that of the normoxia group. The relative p27
kip1
level in b-E2 treatment group was significantly higher
than that of the hypoxia group (Figure 3a, P < 0.01).
Table 1 Analysis of hemodynamic data and right
ventricle hypertrophy index
Group mCAP (mmHg) RVSP (mmHg) (RV/LV+S)%
Normoxia 119.40 ± 8.90 24.90 ± 1.66 25.64 ± 2.19
Normoxia+b-E2 117.32 ± 6.02 25.17 ± 1.20 25.71 ± 1.89
Hypoxia 124.25 ± 3.31 47.36 ± 3.47* 39.01 ± 4.69*
Hypoxia+b-E2 119.39 ± 9.20 35.17 ± 1.67
# 30.90 ± 1.47
#
All values are expressed as mean ± SD (n = 7). *P < 0.01, significant difference
from the normoxia group.
#P < 0.01, significant difference from the hypoxia
group. mCAP: mean carotid artery pressure; RVSP: right ventricular systolic
pressure; RV/LV+S: right ventricle/left ventricle + septum.
Figure 1 Effects of b-E2 on chronic hypoxia-induced pulmonary vascular structure remodeling of rats. (a) Hematoxylin and eosin staining
of pulmonary arterioles (original magnification ×20). (b) Medial wall thickness (MT%) of pulmonary arterioles. (c) Medial wall area (MA%) of
pulmonary arterioles. Scale bars = 50 μm. *P < 0.01, significant difference from the normoxia group.
#P < 0.01, significant difference from the
hypoxia group. Arterioles of external diameter ranged from 50-200 μm, 5-6 vessels per animal, total 40 small arteries for each group, were
obtained. Values are expressed as mean ± SD (n = 40).
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kip1
level between the normoxia and the normoxia+b-E2
group (Figure 3a). The results also showed that the rela-
tive Skp-2 level in hypoxia group was significantly higher
than that of the normoxia group (Figure 3a, P < 0.01).
The relative Skp-2 level in hypoxia+b-E2 group was
significantly lower than that of the hypoxia group (Figure
3a, P < 0.01). In accordance with the results of p27
kip1,
there was no significant change of the Skp-2 relative level
between the normoxia group and the normoxia+b-E2
(Figure 3a).
To further confirm if p27
kip1 and Skp-2 participated in
the process of chronic hypoxia-induced pulmonary artery
remodeling, the lysates of each group of PASMCs were
used to do WB assays. As the results showed, compared
with the normoxia group, the relative p27
kip1 levels was
significant lower in hypoxia group. However, the relative
p27
kip1 levels were markedly higher in all three dosages
of b-E2 treatment groups than that of the hypoxia group
(Figure 3b, P < 0.05). The relative p27
kip1 level in the
b-E2 (10
-5 Mol/L) treated group was nearly 2 folds higher
than in the hypoxia group (Figure 3b, P < 0.01). The data
also revealed that hypoxia exposure notably escalated the
expression of Skp-2 compared with the normoxia group
(Figure 3b, P < 0.01). All three dosages of b-E2 treatment
resulted in significant reduction of Skp-2 versus the
hypoxia group (Figure 3b, P < 0.05).
Protein expression of Akt-P in rat lung tissue and
cultured PASMCs
Our next step focused on phosphorylated Akt which
initiates Skp-2 activation. Similar with Skp-2, the relative
Akt-P level in hypoxia group was significantly higher
than that of the normoxia group in rat lung tissue
Figure 2 Effects of b-E2 on rat PASMCs proliferation under
hypoxia exposure (MTT assay).* P < 0.01, significant difference
from the normoxia group.
#P < 0.01, significant difference from the
hypoxia group. Values are expressed as mean ± SD (n = 3).
Figure 3 Effects of b-E2 on p27 and Skp-2 expression in rat lungs and cultured rat PASMCs. (a) Representative Western blotting analysis
of p27 and Skp-2 protein levels in rat lungs. (b) Representative Western blotting analysis of p27 and Skp-2 protein levels in cultured rat PASMCs.
*P < 0.05, significant difference from the hypoxia group.
#P < 0.05, significant difference from the normoxia group.
$P < 0.05, significant
difference from the hypoxia group.
&P < 0.01, significant difference from the normoxia group. Values are expressed as mean ± SD (n = 3).
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+b-E2 group was significantly lower than that of the
hypoxia group (Figure 4a, P < 0.01).
In accordance with the expression of Skp-2, in cul-
tured PASMCs, hypoxia exposure resulted in notably
elevation of Akt-P versus the normoxia group (Figure
4b, P < 0.01). The expression of Akt-P in the three
dosages of b-E2 treatment groups were all significantly
lower compared with the hypoxia group (Figure 4b,
P < 0.05).
Changes in mRNA levels of p27
kip1 and Skp-2
in rat lung tissue and cultured PASMCs
To further investigate whether p27
kip1 and Skp-2 were
regulated at transcriptional level, the mRNA levels of
p27
kip1,S k p - 2a n db-actin in lung tissue were analyzed
by RT-PCR. The results of RT-PCR showed that there
were no significant differences between all groups in
relative p27
kip1 mRNA level, whether in rat lung tissue
or in cultured PASMCs (Figure 5a, b).
On the other hand, the relative Skp-2 mRNA level in
the hypoxia group was significantly elevated compared
with that of the normoxia group in rat lung tissue (Fig-
ure 5a, P < 0.01). In the hypoxia+b-E2 group, the rela-
tive mRNA level of Skp-2 was significantly reduced
compared with the hypoxia group (Figure 5a, P <0 . 0 1 ) .
There was no significant difference between the relative
Skp-2 level in rat lung tissue of normoxia group and
normoxia+b-E2 (Figure 5a). In cultured PASMCs, the
relative Skp-2 mRNA level was notably increased after
hypoxia exposure compared with the normoxia group
(Figure 5b, P < 0.01). All three different dosages of b-E2
treatment decreased the Skp-2 mRNA level in cultured
PASMCs exposed to hypoxia (Figure 5b, P < 0.05).
Taken together, these results suggested that
hypoxia exposure resulted in PVSR and pulmonary
Figure 4 Effects of b-E2 on Akt-P expression in rat lungs and cultured rat PASMCs. (a) Representative Western blotting analysis of Akt-P
protein levels in rat lungs. (b) Representative Western blotting analysis of Akt-P protein levels in cultured rat PASMCs. *P < 0.01, significant
difference from the hypoxia group.
#P < 0.05, significant difference from the normoxia group. Values are expressed as mean ± SD (n = 3).
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effects on hypoxia-induced PVSR and pulmonary
hypertension. The elevation of p27
kip1 and reduction of
Skp-2 may play important roles in b-E2 attenuation
effects on PVSR and HPH. The below diagram may
elucidate the mechanism we explored in the present
study (Figure 6).
Discussion
Pulmonary hypertension is characterized by vasocon-
striction and remodeling of small pulmonary arteries
[3,8]. Media hyperplasia is the main pathologic change
of the remodeling pulmonary arteries. The nature of the
structural alteration and the mechanisms responsible for
the pulmonary vasculature remodeling are complex and
not yet fully elucidated [32]. Pulmonary hypertension
accompanied with pulmonary vascular medial hyperpla-
sia is mainly due to excessive PASMCs proliferation
[30,32].
Charron and colleagues revealed cell cycle as a critical
therapeutic target to prevent vascular diseases [34]. As
an important CKI and anti-oncogene protein, p27
kip1,i s
now being investigated for its inhibitory effects on can-
cer and vascular proliferative diseases [49,50]. Diez-Juan
et al elucidated p27
kip1 f u n c t i o n sa sas u p p r e s s o ri n
VSMCs proliferation, neovascularization, restenosis and
atherosclerosis [51]. On the other hand, Skp-2 also
draws lots of attentions from researchers for being an
important proto-oncogene protein and the specific
degradation ligase for p27
kip1. Now, considerable studies
focus on the therapeutic potential of p27
kip1 and Skp-2
on cancers or vascular diseases [47,52]. To date, there
are few studies about the role of p27
kip1 on hypoxic pul-
monary hypertension. More work need to be done to
Figure 5 Effects of b-E2 on mRNA expression in rat lungs and cultured PASMCs. (a) Analysis of p27 and Skp-2 mRNA levels in rat lungs. (b)
Analysis of p27 and Skp-2 relative mRNA levels in cultured rat PASMCs. *P < 0.01, significant difference from the hypoxia group.
#P < 0.01,
significant difference from the normoxia group.
$P < 0.05, significant difference from the hypoxia group.
&P < 0.01, significant difference from the
normoxia group. Values are expressed as mean ± SD (n = 3).
Figure 6 Illustration of the potential mechanism of b-E2 effects
on HPH .
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Page 8 of 11elucidate the beneficial effects of p27
kip1 on PVSR and
HPH. As mentioned above, estrogen could effectively
attenuate pulmonary hypertension and anti-proliferation
in proliferative vascular diseases. Therefore, in this study
we employed estrogen to explore the roles of p27
kip1
and Skp-2 in the evolution of PVSR and HPH.
It is interesting that p27
kip1 and Skp-2 indeed involved
in the protective effects of b-E2 on the chronic hypoxia
exposed rats. In the present study on the rat models,
chronic hypoxia exposure resulted in significantly ele-
vated RVSP, increased RV/LV+S, MT% and MA%, and
marked media thickening of pulmonary arterioles. Wes-
tern blotting data showed that hypoxia diminished the
expression of p27
kip1 along with the escalation of Skp-2
and Akt-P. Beta-estradiol application reversed the reduc-
tion of p27
kip1, elevation of Skp-2 and Akt-P, accompa-
nied with the attenuation of pulmonary hypertension
and PVSR induced by hypoxia. Consistent with the
study in vivo, experiments in vitro also revealed the
anti-proliferation effect of b-E2 on PASMCs. Moreover,
the study in vitro also demonstrated that hypoxia
resulted in marked reduction of p27
kip1 and augmenta-
tion of Skp-2 and Akt-P, which can be effectively
reversed by b-E2 treatment.
As the WB data showed, b-E2 increased the expres-
sion of p27
kip1 protein in dosage-dependent manner.
Moreover, Skp-2 and Akt-P decreased in direct pro-
portion to the dosage of b-E2. On the other hand, RT-
PCR data showed that p27
kip1 mRNA was not
obviously changed by b-E2 application, neither in vivo
nor in vitro experiments. The results are consistent
with those reported by Hengst L [53]. In contrast with
our results, Yu et al found that the p27
kip1 mRNA
levels were significantly changed in hypoxia-exposed
mice models compared with the heparin treated mice
[42]. They also demonstrated in their study that
p27
kip1 protein was up-regulated by heparin. In our
opinion, different animal species and varied interven-
tions in the researches may explain the discrepancy.
Unlike p27
kip1, Skp-2 was found to be both changed at
mRNA and protein levels, indicating that b-E2 can
decrease Skp-2 expression both through transcriptional
and posttranscriptional mechanisms. In accordance
with the study of Karin et al [46], the present study
also demonstrated that the Akt signal pathway may
account for the reduction of Skp-2.
Series of studies on estrogen testified that it could
effectively alleviate various types of vascular diseases.
However, there are many controversies over the protec-
tive effects of estrogen, especially over the anti-prolifera-
tion effect [54-61]. In this study, we found that b-E2
significantly inhibited PASMCs growth under hypoxia
condition, both in vivo and in vitro. In our opinion, the
different experimental conditions, different animal
models and different treatments may explain the
controversies.
The estradiol metabolite, 2-methoxyestradiol (2ME),
was found able to abrogate injury-induced neointima
formation to decrease proliferating SMCs and to up-reg-
ulate the expression of P27
kip1 [62]. Other researchers
also revealed that 2ME can effectively attenuate bleomy-
cin-induced pulmonary hypertension and fibrosis in rats
[63]. Based on these studies, whether 2ME mediate the
inhibition effect of b-E2 on PASMCs and elevation of
P27
kip1 in chronic hypoxia-induced pulmonary hyperten-
sion remains to be determined.
Chronic hypoxia exposure increases intimal thickness
of arterioles by causing hypertrophy and hyperplasia of
the endothelial cells [30,64]. After being released from
endothelium under chronic hypoxia condition, num-
bers of potent vasoactive substances then promote
contraction and proliferation of PASMCs [65,66].
Investigations revealed that endothelial cells are closely
associated with the PASMCs proliferation in the pro-
cess of HPH. Though studies have shown the effects of
estrogen on ECs including repressing adhesion mole-
cules expression and enhancing expression of cytokines
[27,67,68], more work should be done to explore
whether estrogen could elevate the expression of
P27
kip1 in endothelium and inhibit the proliferation of
ECs under chronic hypoxia.
Taken together, our results demonstrated that b-E2
kept p27
kip1 from being degraded through decreasing
the production of Skp-2. Subsequently, p27
kip1 pre-
vented the chronic hypoxia induced PVSR and pulmon-
ary hypertension through its inhibitory effects on
PASMCs. Therefore, we concluded that stabilized
p27
kip1 by b-E2 application indeed participated in the
attenuation of PVSR and HPH. The down-regulated
Skp-2 through Akt signal pathway may be responsible
for the increased expression of p27
kip1.
Study limitations
(1) Though our data showed strong evidence that b-E2
could stabilize the expression of p27
kip1 and attenuate
PVSR and HPH, whether it could have the same bene-
ficial effects on humans with PAH remains unclear.
(2) The gender differences were not studied, that is,
whether b-E2 has the same protective effects on
female rats as males needs to be explored. Since male
rat models were employed in the study, whether male
hormones involved in b-E2 attenuating HPH should
also be furthered. (3) Though the study showed evi-
dence of the inhibitory effects of b-E2 on PASMCs, it
still seems somewhat insufficient for not considering
the ECs.
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Page 9 of 11Conclusions
In brief, this study reveals that stabilized p27
kip1 may be
a partial mechanism by which b-E2 exerts its protective
effects on PVSR and HPH. Down-regulation of Skp-2
through Akt signal pathway may account for the
increased expression of p27
kip1 after b-E2 application.
So, up-regulating the production of p27
kip1 or down-reg-
ulating the expression of Skp-2 might be new strategies
to treat PVSR and HPH.
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